Abstract
Prior to the advent of combination antiretroviral therapy, pericardial effusion, pericarditis, and cardiac tamponade were important clinical problems in HIV-infected patients, especially those with AIDS diagnoses. In the current HIV treatment era, clinically significant pericardial disease is uncommon. Infectious causes, primarily mycobacterial, and malignancy are the most common identifiable causes of clinically significant pericardial disease in HIV-infected patients. The evaluation and management of pericardial disease does not differ fundamentally in HIV-infected patients compared to the general population. While uncommon in resource-rich settings, tuberculous pericarditis is a concern in HIV-infected patients, and empiric treatment for this may be a consideration in some clinical settings with negative diagnostic evaluations. The role of adjunctive corticosteroids with antituberculous therapy remains controversial.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Rerkpattanapipat P, Wongpraparut N, Jacobs LE, Kotler MN. Cardiac manifestations of acquired immunodeficiency syndrome. Arch Intern Med. 2000;160(5):602–8.
Heidenreich PA, Eisenberg MJ, Kee LL, et al. Pericardial effusion in AIDS. Incidence and survival. Circulation. 1995;92(11):3229–34.
Lind A, Reinsch N, Neuhaus K, et al. Pericardial effusion of HIV-infected patients? Results of a prospective multicenter cohort study in the era of antiretroviral therapy. Eur J Med Res. 2011;16(11):480–3.
Ntusi N, O’Dwyer E, Dorrell L, et al. HIV-1-related cardiovascular disease is associated with chronic inflammation, frequent pericardial effusions, and probable myocardial edema. Circ Cardiovasc Imaging. 2016;9(3):e004430.
LeWinter MM. Clinical practice. Acute pericarditis. N Engl J Med. 2014;371(25):2410–6.
Hakim JG, Ternouth I, Mushangi E, Siziya S, Robertson V, Malin A. Double blind randomised placebo controlled trial of adjunctive prednisolone in the treatment of effusive tuberculous pericarditis in HIV seropositive patients. Heart. 2000;84(2):183–8.
Elliott AM, Luzze H, Quigley MA, et al. A randomized, double-blind, placebo-controlled trial of the use of prednisolone as an adjunct to treatment in HIV-1-associated pleural tuberculosis. J Infect Dis. 2004;190(5):869–78.
Mayosi BM, Ntsekhe M, Bosch J, et al. Prednisolone and mycobacterium indicus pranii in tuberculous pericarditis. N Engl J Med. 2014;371(12):1121–30.
Imazio M, Belli R, Brucato A, et al. Efficacy and safety of colchicine for treatment of multiple recurrences of pericarditis (CORP-2): a multicentre, double-blind, placebo-controlled, randomised trial. Lancet. 2014;383(9936):2232–7.
Glesby MJ. HIV and Cardiovascular Risk. New York: Oxford University Press; 2011.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Glesby, M.J. (2019). Pericardial Disease. In: Myerson, M., Glesby, M. (eds) Cardiovascular Care in Patients With HIV. Springer, Cham. https://doi.org/10.1007/978-3-030-10451-1_11
Download citation
DOI: https://doi.org/10.1007/978-3-030-10451-1_11
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-10450-4
Online ISBN: 978-3-030-10451-1
eBook Packages: MedicineMedicine (R0)